Sol-Gel Technologies (SLGL) Other Non Operating Income (2021 - 2023)
Sol-Gel Technologies (SLGL) posted quarterly Other Non Operating Income of $41000.0 for Q4 2023, up 192.86% quarter-over-quarter from $14000.0 in Q3 2023.
Powered by 
Analysis
Sol-Gel Technologies (SLGL) Other Non Operating Income (2021 - 2023) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Other Non Operating Income for 2 consecutive years, with $41000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Other Non Operating Income changed N/A year-over-year to $41000.0; the TTM figure through Dec 2023 stood at $579000.0 (changed N/A YoY), while the FY2023 annual figure was $55000.0, changed N/A from the prior year.
- Other Non Operating Income climbed to $41000.0 in Q4 2023 per SLGL's latest filing, from $14000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $554000.0 in Q3 2021 and bottomed at -$30000.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 41,000.00 |
| Sep 30, 2023 | 14,000.00 |
| Dec 31, 2021 | -30,000.00 |
| Sep 30, 2021 | 554,000.00 |